Why Wall Street Can't Get Enough of This Dividend King

AbbVie inherited its Dividend King status, but has proven to be a good dividend steward. The company's 2.7% yield is well-above the pharmaceutical average.

The Motley Fool • 10 hours ago

AbbVie: A Dividend Fortress At An Appealing Price Tag

AbbVie earns a buy rating, supported by accelerating top and bottom-line growth and a compelling valuation at 18x forward P/E. ABBV offers a 2.7% forward dividend yield, outperforming peers by 68%, and maintains a 12-year streak of dividend growth. Dividend growth remains central to ABBV's shareholder-friendly capital allocation, with a payout ratio of 59% and consensus expectations for continued increases.

Seeking Alpha • Jul 24, 2026

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Jul 24, 2026

Netflix, AbbVie, Cerebras Systems And An Energy Stock On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes AbbVie Inc. (NYSE:ABBV).

Benzinga • Jul 24, 2026

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody®-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared with investigator's choice of chemoimmunotherapy (CIT) of either rituximab plus gemcitabine plus oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) in adults.

Business Wire • Jul 23, 2026

Will AbbVie's Oncology Franchise Remain Under Pressure in Q2?

ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.

Zacks Investment Research • Jul 22, 2026

3 Reasons to Buy AbbVie Stock Like There's No Tomorrow

AbbVie's biggest growth drivers are performing very well. The company has a strong pipeline of attractive candidates.

The Motley Fool • Jul 21, 2026

AbbVie (ABBV) Beats Stock Market Upswing: What Investors Need to Know

AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior day.

Zacks Investment Research • Jul 21, 2026

How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?

AbbVie will fund this acquisition with debt, leaving its cash reserves intact. The company should maintain its dividend program as it did after previous massive acquisitions.

The Motley Fool • Jul 20, 2026

3 Biggest Pharma Giants: Buy, Sell or Hold?

The three biggest US pharma names by market cap trade at very different setups right now: Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) at $247.02 screens as the most compelling on fundamentals, Eli Lilly (NYSE:LLY) at $1,156.63 looks fully valued, and AbbVie (NYSE:ABBV) at $244.11 appears stretched relative to its growth outlook.

24/7 Wall Street • Jul 19, 2026